Researching Myocarditis Risk in Adults Following COVID-19 mRNA Vaccination
Reports of myocarditis after administration of COVID-19 messenger RNA (mRNA) vaccines have been documented, especially among males. However, the incidence rates in the general population are not known, and current information reveals that pericarditis diagnostic codes, rather than myocarditis diagnostic codes, are being used to estimate incidence rates. Read more.

FDA Expands Eligibility for mRNA COVID-19 Vaccine Booster for All Adults
On November 19, 2021, the FDA announced that it amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals aged 18 years and older after completion of primary vaccination with any FDA-authorized or approved COVID-19 vaccine. Read more.

Moderna Announces Measures to Address Omicron SARS-CoV-2 Variant
In a press release on November 26, 2021, the manufacturer, Moderna, announced updates to its approach to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant. The manufacturer indicated that the recently reported Omicron variant includes mutations noticed in the Delta variant that are believed to boost transmissibility and mutations seen in the Beta and Delta variants that are believed to promote immune escape. Read more.